GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abivax SA (FRA:2X10) » Definitions » Future 3-5Y EPS without NRI Growth Rate

Abivax (FRA:2X10) Future 3-5Y EPS without NRI Growth Rate : 29.81 (As of Jul. 25, 2025)


View and export this data going back to 2023. Start your Free Trial

What is Abivax Future 3-5Y EPS without NRI Growth Rate?

Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, Abivax's Future 3-5Y EPS without NRI Growth Rate is 29.81.

Competitive Comparison of Abivax's Future 3-5Y EPS without NRI Growth Rate

For the Biotechnology subindustry, Abivax's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Abivax's Future 3-5Y EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Abivax's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Abivax's Future 3-5Y EPS without NRI Growth Rate falls into.


;
;

Abivax  (FRA:2X10) Future 3-5Y EPS without NRI Growth Rate Explanation

Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

Abivax Future 3-5Y EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Abivax's Future 3-5Y EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Abivax Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abivax SA (FRA:2X10) » Definitions » Future 3-5Y EPS without NRI Growth Rate
Comparable Companies
XPAR:VLA XPAR:IVA XPAR:MEDCL XPAR:DBV XPAR:NANO XPAR:GNFT XPAR:IPH XPAR:ALCLS XPAR:OSE XPAR:TNG VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:UCB XBRU:ARGX ONC XKRX:068270 BNTX
Traded in Other Exchanges
ABVX:USA AAVXF:USA 0RA9:UK ABVX:France 2X1:Germany 2X1:Germany
Address
7-11 boulevard Haussmann, Paris, FRA, 75009
Website
https://www.abivax.com
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.

Abivax Headlines

No Headlines